Skip to content
MARKETS / BALCAO / CPMD
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Cannapharmarx, Inc. CPMD

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.4M
▲ 66.1% YoY
$-11.1M
$-794,621
In brief

What this company does

CannaPharmaRx, Inc. (“CPMD”, “we”, “our”, or the “Company”) specializes in the acquisition, development, and operation of cannabis cultivation facilities in Canada. On January 6, 2022, we entered into a 20-year operating lease for the use of a 55,000 square foot facility located in Cremona, Alberta, Canada (the “Facility”). During 2022, we recommissioned the Facility into an indoor cannabis farm with 10 growing rooms and one drying and packing room. We received an operating license from Health Canada on December 9, 2022, and a cannabis license from the Canada Revenue Agency (“CRA”) on December 22, 2022, and commenced cannabis production during the year ended December 31, 2023. We plan to grow by increasing our production capacity at the Facility to support sales of cannabis to the European markets, with a focus on Germany and Israel.

Written from the business description in CannaPharmaRx, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 1.4M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.4 · Net income -11.1
2M-8M-16M200920112013201520172019202120232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−817 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -245.8% · Net -817.2%
-500%-1000%200920112013201520172019202120232025
ROE
FY2023 · ROE 142.1%
50%100%-500%200920112013201520172019202120232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -0.8
-2M200920112013201520172019202120232025
Net buybacks $ Dividends $
FY2020 · Dividends — · Net buybacks 0.0
4000080000201820192020

Total assetsUSD 7.0M
EquityUSD -30.2M
CashUSD 1,804.00
Current ratio0.04×

Equity funds -430% of total assets.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.0····
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.0
EBITDA $B···−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·····
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.00.0····
Net income $B−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.0
Free cash flow $B−0.0−0.0−0.0···−0.0−0.0·−0.0−0.0−0.0·····
EPS, diluted $−0.02−0.020.01−0.04−0.12−0.49−0.66−0.170.00−0.06−0.77−0.36−0.04−0.04−0.040.24·
Dividend / sh $·················
Payout %·················
ROE %··142.1−386.1··−895.4··········
Shares out B0.660.660.440.270.130.050.040.020.020.020.020.020.000.000.000.000.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 30 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image